LOGIN
Extended-release triamcinolone acetonide (FX006) versus placebo in knee osteoarthritis treatment
January 2019
Extended-release triamcinolone acetonide (FX006) versus placebo in knee osteoarthritis treatment
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study
J Bone Joint Surg Am. 2018 Apr 18;100(8):666-677Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
486 patients with Kellgren-Lawrence grade II-III knee osteoarthritis were randomized to one of three groups: single intraarticular injection of 32mg extended-release triamcinolone (FX006; Flexion Therapeutics); single intraarticular injection of 40mg triamcinolone acetonide crystalline suspension (TAcs); or single intraarticular injection of placebo saline. Patients were assessed primarily with re...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.